A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active:	Yes
Cancer Type:	Cancer-Related Syndrome Leukemia Myelodysplastic Syndromes (MDS)	NCT ID:	NCT03802695
Trial Phases:	Phase I	Protocol IDs:	OGFT001-001 (primary) NCI-2019-01953
Eligibility:	18 - 65 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Orca Biosystems, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT03802695

Summary

This study will evaluate the safety, tolerability, and efficacy of engineered donor
grafts ("OrcaGraft"/"Orca-Q") in participants undergoing myeloablative allogeneic
hematopoietic cell transplant transplantation for hematologic malignancies.

Treatment Sites in Georgia

Emory University Hospital - Atlanta
1364 Clifton Road NE
Atlanta, GA 30322
www.emoryhealthcare.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.